The tweet was deleted by the author.
But we saved everything 🙂.
CG Oncology, Inc. has presented five new research posters focused on cretostimogene at the ASCO Genitourinary Cancers Symposium in San Francisco.
The posters draw from studies including CORE‑008 (A and B), BOND‑003 (C and P), and the company’s Expanded Access Program, highlighting ongoing scientific innovation in bladder cancer and genitourinary oncology. With this comprehensive update, CG Oncology, Inc. aims to reinforce its position in advancing novel therapies for the field. Further details on the research can be accessed through the provided links.